MTOR and prostate cancer: To further define this, we evaluated changes in LC3A/B accumulation, LC3B lipidation levels, and mTOR signaling in bafilomycin A1–sensitive (R5) and bafilomycin A1–nonsensitive (R4) prostate cancer organoids over a time-course experiment (Fig. 5E).